Skip to main content

Table 1 Clinical characteristics and biochemical variables in women with and without PCOS

From: Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study

Parameters

PCOS

non-PCOS

P value

 

Total

Lean

Overweight

Total

Lean

Overweight

(PCOS vs non-PCOS)

N

61

30

31

56

38

18

 

Age, yrs

26(21–31)

24.5(21–31.25)d

26(23–31)

26(24–29)

25.5(24–27)

29.5(26.75–34)a

0.415

BMI, kg/m2

24.98(21.7–26.98)

21.7(19.41–23.3)d

26.89(25.63–27.77)c,f

22.06(21–24.91)

21.59(20.41–22.11)

27.48(24.91–27.85)a

0.062

WHR

0.87 ± 0.07

0.83 ± 0.07d

0.91 ± 0.06 c,f

0.85 ± 0.07

0.82 ± 0.06

0.9 ± 0.07a

0.043

FAT%

32.5(28.5–37.3)

28.8(22.85–31.6)d

37.55(35.88–41.55)c,f

31.2(23.7–38.6)

24.25(21.3–27.3)

38.6(36.5–41.4)a

0.772

AUCglucose

10.69(9.38–12.54)

9.77(7.89–11.79)

11.63(10.49–13.06)c,f

9.69(8.1–11.66)

8.79(7.51–10.74)

10.73(9.73–12.6)a

0.018

AUCinsulin

107.57(54.18–161.07)

81.25(48.38–130.12)

137.51(91.62–193.94)c,f

73.46(45.57–114.58)

68.93(44.48–98.54)

83.72(43.96–137.69)

0.017

HOMA-IR

2.21(1.39–4.2)

1.62(0.92–2.31)d

3.47(2.14–4.96)c

1.93(1.19–2.69)

1.61(1–2.25)

3.22(1.85–4.46)a

0.066

Matsuda Index

65.61(40.35–105.8)

101.18(69.86–152.44)

49.8(37.46–63.53)c,f

100.13(63.46–154.98)

110.19(86.21–166.93)

70.21(42.8–113.74)a

0.008

DI

8.67(4.55–16.1)

14.17(7.23–20.69)d

6.14(2.37–9.79)c,f

10.94(5.48–22.47)

18.09(8.81–23.94)

5.49(1.98–7.43)a

0.213

TG, mmol/L

1.17(0.8–1.53)

0.87(0.72–1.18)d

1.26(1.09–1.78)f

1.29(0.77–1.6)

1.07(0.66–1.6)

1.48(1.15–1.93)a

0.704

TC, mmol/L

4.42(4.01–4.88)

4.14(3.91–4.75)b,d

4.6(4.01–5.18)c

4.2(3.41–4.89)

3.56(3.34–4.6)

4.66(4.34–5.16)a

0.024

HDL-C, mmol/L

1.25(1.08–1.54)

1.45(1.27–1.67)d

1.18(1.02–1.25)c,f

1.44(1.21–1.57)

1.47(1.34–1.65)

1.18(1.04–1.31)a

0.218

LDL-C, mmol/L

2.77 ± 0.83

2.49 ± 0.68d

3.04 ± 0.89c,f

2.55 ± 0.58

2.35 ± 0.53

2.96 ± 0.48a

0.101

hsCRP, mg/L

1.09(0.33–3.03)

0.54(0.22–1.35)d

2.04(0.55–4.15)c,f

0.37(0.17–1.65)

0.27(0.17–0.44)

1.82(0.74–3.91)a

0.014

T, nmol/

2.36(1.66–2.75)

2.36(1.4–2.83)b,d

2.4(1.83–2.63)c,e

1.63(1.39–1.87)

1.6(1.4–1.79)

1.73(1.02–2.03)

< 0.001

SHBG, nmol/L

23.3(14.6–45.7)

35.05(20.58–66.28)

18.7(11.3–29.7)c,e,f

41.75(30.73–60.05)

50.2(38.7–62.75)

32.85(18.58–39.6)a

< 0.001

FAI

9.29(4.46–15.25)

5.57(2.81–11.43)b

12.54(7.27–19.73)c,e,f

3.61(2.48–5.2)

3.19(2.45–4.44)

5.4(2.61–7.73)a

< 0.001

A2, μg/dL

5.9(4.22–7.98)

4.52(2.14–6.97)

6.49(4.83–9.5)c,e

2.85(2.24–5.52)

2.97(2.26–5.64)

2.73(2.11–5.83)

0.019

  1. Data are shown as the mean ± SD for variables with a normal distribution and median with the interquartile range (25–75%) for skewed variables. For variables with a normal distribution, an independent samples t-test was performed to compare variables between two groups; a one-way ANOVA followed by the LSD test was performed among the four subgroups of women (lean control, overweight control, lean PCOS, and overweight PCOS). For variables with a skewed distribution, the Mann-Whitney U test was performed to compare variables between the two groups; the Kruskal-Wallis test followed by the Mann-Whitney U test was performed for the four subgroups of women
  2. BMI Body mass index, WC Waist circumference, WHR Waist hip ratio, FAT% Body fat percentage, AUCglucose Area under curve for OGTT glucose, AUCinsulin Area under curve for OGTT insulin, HOMA-IR Homeostasis model assessment of insulin resistance, DI Disposition index, TG Triglyceride, TC Total cholesterol, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, hsCRP high sensitivity C reactive protein, T Total testosterone, SHBG Sex hormone binding globulin, FAI Free androgen index A2 androstenedione
  3. To convert testosterone to ng/ml, divide by 3.467; To convert cholesterol to mg/dL, divide by 0.02586; to convert triglycerides to mg/dL, divide by 0.01129; to covert glucose to mg/dL, divide by 0.05551; to convert total testosterone to ng/ml, divide by 3.467
  4. aP < 0.05 for lean non-PCOS women vs overweight non-PCOS women
  5. bP < 0.05 for lean non-PCOS women vs lean PCOS women
  6. cP < 0.05 for lean non-PCOS women vs overweight PCOS women
  7. dP < 0.05 for overweight non-PCOS women vs lean PCOS women
  8. eP < 0.05 for overweight non-PCOS women vs overweight PCOS women
  9. f P < 0.05 for lean PCOS women vs overweight PCOS women